• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Thoracic Society (ATS) 2022

May 13 - 18, 2022

  1. Tezepelumab
  2. Benralizumab
  3. Budesonide/Glycopyrrolate/Formoterol (PT010)
  4. PT027
  5. Tozorakimab (MEDI3506)
  6. ISAR/CHRONICLE
  7. PRECISION
  8. NOVELTY
  9. SABINA
  10. CARBON
  11. General Asthma/COPD
  12. Real-World Evidence - COPD
  13. Real-World Evidence - Asthma
  14. Early Biopharmaceuticals R&D

Html

Clinically meaningful improvements in St George’s Respiratory Questionnaire score with tezepelumab compared with placebo in patients with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study

Html

Clinical responses to treatment with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study

Html

Characteristics of asthma exacerbations that required hospitalization in patients with severe asthma receiving tezepelumab versus placebo: results from the phase 3 NAVIGATOR study

Html

Tezepelumab reduces biomarkers of airway remodeling, MMP-10 and MMP-3: results from the phase 3 NAVIGATOR study

Html

Long-term efficacy of benralizumab in patients with severe asthma directly transitioning from the ANDHI double-blind to the ANDHI in Practice open-label extension substudy

Html

Benralizumab improves mannitol airway hyperresponsiveness in uncontrolled severe eosinophilic asthma

Html

Towards Clinical Remission in Severe Asthma: An Analysis of Patients Treated with Benralizumab in the Phase 3b ANDHI Trial

Html

Rescue Medication Use Before, During, and After COPD Exacerbations: Post-Hoc Analysis of the ETHOS Study

Html

Relationship Between On-treatment Rescue Medication Use, Exacerbation Rates, and Health-related Quality of Life in Chronic Obstructive Pulmonary Disease: Post-hoc Analysis of the ETHOS Study

Html

A Post-hoc Analysis of the Effect of Smoking Status on COPD Exacerbation Reductions with Budesonide/Glycopyrrolate/Formoterol Fumarate in Patients with COPD in the ETHOS Study

Html

Reducing environmental impact of pressurised metered dose inhalers: relative bioavailability of budesonide/glycopyrronium/formoterol with different propellant formulations in healthy subjects

Html

Efficacy and safety of albuterol/budesonide in mild-to-moderate asthma: Results of the DENALI study

Html

Efficacy and safety of albuterol/budesonide versus albuterol administered as-needed in patients with moderate-to-severe asthma: results of the MANDALA study

Html

Safety, pharmacokinetics and immunogenicity of the anti-interleukin-33 antibody, tozorakimab: results of a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease

Html

Proof of mechanism for anti-interleukin-33 antibody tozorakimab in a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease

Html

Exacerbation Burden and Biologic Outcomes in US Patients with Severe Asthma and Significant Smoking History or COPD: Results from the CHRONICLE Study

Html

Learnings from More Than 500 Patients Hospitalized for Severe Asthma in the United States

Html

Impact of initiating biologics in patients with severe asthma and on long-term oral corticosteroids or rescue steroids (GLITTER)

Html

Prevalence of Comorbidities in Adults with Severe Asthma: Results from the International Severe Asthma Registry (ISAR)

Html

Meaningful Change in Asthma Impairment and Risk Questionnaire (AIRQ®) Score: Assessing Minimally Important Difference (MID)

Html

Impact of the COVID-19 pandemic on exacerbation rates in patients with asthma and/or Chronic Obstructive Pulmonary Disease in the NOVELTY study'

Html

Relationships Between Symptoms and Lung Function in Asthma and/or Chronic Obstructive Pulmonary Disease in the NOVELTY study

Html

Physiological phenotypes of patients with asthma and/or COPD using 129Xe MRI

Html

Prototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates

Html

Are patients treated according to GINA? Treatment and exacerbation patterns in UK primary care from SABINA heatmaps

Html

SABINA Jr UK: The association between SABA prescriptions and frequency of asthma exacerbations in a paediatric cohort

Html

Real-world impact of non-clinical inhaler switching on asthma or COPD patients: a systematic review

Html

An Implementation Study of AMAZE: An Asthma Disease Management Platform

Html

The burden of asthma in patients receiving low-dose ICS/LABA – an analysis from a real world survey

Html

Identifying unmet needs in moderate asthma using Hidden Depths methodology

Html

Adverse Outcomes Post-initiation of Systemic Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: A Long-term Observational UK-based Study

Html

Effect of biologics on allergic response and airway hyperresponsiveness: a systematic literature review

Html

Asthma deaths at home are unchanged despite declining mortality in other settings: US death certificate data from 2000-2019

Html

Incremental Cost Burden Among Patients With Severe Uncontrolled Asthma In US

Html

Geographic Variation In Disease Burden Among Patients With Severe Persistent Asthma In The US

Html

Patient preferences for biologic treatments for severe asthma: pilot results from a discrete choice experiment

Html

Characteristics and outcomes of patients with severe eosinophilic asthma treated with benralizumab enrolled in the Connect 360 patient support programme

Html

Annual Inhaled Corticosteroid, Short-acting Beta2-Agonist and Systemic Corticosteroid Exposure in Adolescents and Adults with Asthma in the United States

Html

Patterns of Systemic Corticosteroid Exposure and Adverse Health Conditions in US Children with Asthma in Relation to Short-acting Beta2-agonist Utilization

Html

Establishing relevant emphysema model using iPSC-AT2 co-culture with fibroblasts

Html

Prevention of replicative senescence in IPF by telomerase enhancement

Html

Proteomic analysis of sputum from COPD patients reveal that decreased PIGR and IgA correlate with exacerbation frequency and haemophilus influenzae burden

Html

Transfer of microRNA through extracellular vesicles propagate airway epithelial cells senescence in COPD

Html

Intratracheal induction of lung senescence by doxorubicin to evaluate senolytics

Html

Airway epithelial JAK-STAT gene signatures identify a cluster of COPD patients with increased blood neutrophils

Html

Identification of a new IgG mAb format with enhanced complement-mediated effector function and extended half-life

Html

Characterization of a novel murine COPD model to study mechanistic disease drivers and to identify new drug targets

Html

Endotoxin abundance in house dust mite drives asthma phenotype in vivo

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice